St. John, Canada Clinical Trials

A listing of St. John, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 12 clinical trials
featured
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

This is an open-label, randomized (1:1), multicenter, Phase 3 clinical trial evaluating the safety and efficacy of nivolumab in combination with investigational agent sitravatinib compared to docetaxel in patients with advanced non-squamous NSCLC who have previously experienced radiographic disease progression on or after treatment with platinum-based chemotherapy in combination with …

nivolumab
cancer
advanced non-squamous non-small cell lung cancer
platinum-based chemotherapy
non-squamous non-small cell lung cancer
Saint John Regional Hospital
 (2.1 away) Contact site
  • 213 views
  • 28 Jul, 2021
  • +188 other locations
Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

The purpose of this study is to evaluate the effect of Sodium Zirconium Cyclosilicate (SZC) on arrhythmia-related cardiovascular outcomes in participants on chronic hemodialysis with recurrent hyperkalemia.

Research site
 (1.2 away) Contact site
  • 0 views
  • 02 Aug, 2021
  • +252 other locations
Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)

This is a Phase III, randomized, parallel-arm, placebo controlled, double blind, multicenter study assessing the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected stage II-III NSCLC who are MRD+ post surgery

lung carcinoma
cancer chemotherapy
durvalumab
Research Site
 (1.2 away) Contact site
  • 102 views
  • 04 Aug, 2021
  • +245 other locations
Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

This is a Phase III double-blind, placebo-controlled study of Durvalumab versus Placebo in patients with stage II-III NSCLC who are MRD-positive following curative intent therapy.

lung carcinoma
durvalumab
Research site
 (1.2 away) Contact site
  • 0 views
  • 04 Aug, 2021
  • +186 other locations
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS) Chronic Myelomonocytic Leukemia (CMML) or Low-Blast Acute Myelogenous Leukemia (AML)

The purpose of this study is to determine whether the combination of pevonedistat and azacitidine improves event-free survival (EFS) when compared with single-agent azacitidine. (An event is defined as death or transformation to AML in participants with MDS or CMML, whichever occurs first, and is defined as death in participants …

pevonedistat
myelomonocytic leukemia
leukemia
myelodysplastic syndromes
azacitidine
Saint John Regional Hospital
 (1.2 away) Contact site
  • 341 views
  • 24 Jul, 2021
  • +319 other locations
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming …

immunostimulant
erbb2
carcinoma
tamoxifen
core needle biopsy
Atlantic Health Sciences Corporation-Saint John Regional Hospital
 (1.2 away) Contact site
  • 598 views
  • 25 Jul, 2021
  • +318 other locations
A Phase 3 Efficacy Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer

A study of zolbetuximab (IMAB362) plus mFOLFOX6 versus placebo plus mFOLFOX6 in subjects with Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Why is this study being done? SPOTLIGHT is a new clinical study for adult patients who have any of: advanced unresectable gastric …

Site CA15009
 (1.2 away) Contact site
  • 484 views
  • 23 Jul, 2021
  • +237 other locations
Bentracimab (PB2452) in Ticagrelor-treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure

This is a multi-center, open-label, prospective single-arm study of reversal of the antiplatelet effects of ticagrelor with bentracimab (PB2452) in patients who present with uncontrolled major or life-threatening bleeding or who require urgent surgery or invasive procedure. Approximately 200 patients will be enrolled from approximately 200 centers in North America, …

blood transfusion
haemostasis
coronary artery bypass graft
ticagrelor
packed red blood cells
Saint John Regional Hospital
 (1.2 away) Contact site
  • 0 views
  • 04 Aug, 2021
  • +49 other locations
Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

RATIONALE: Participating in a physical activity program designed to increase free time physical activity and receiving written health education materials may influence the chance of cancer recurring as well as impact on physical fitness, psychological well-being and the quality of life of patients who have undergone surgery and chemotherapy for …

cancer
cancer treatment
immunomodulators
fatigue
colon cancer
Regional Health Authority B, Zone 2
 (1.2 away) Contact site
  • 397 views
  • 23 Jul, 2021
  • +50 other locations
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated Myelofibrosis (MF) and anemia on concomitant Janus kinase 2 (JAK2) inhibitor therapy and who require red blood cell count (RBC) transfusions. The study is divided …

bilateral oophorectomy
cancer
vasectomy
anemia
Saint John Regional Hospital
 (1.2 away) Contact site
  • 0 views
  • 04 Aug, 2021
  • +157 other locations